Palit, S. A. L., Dorp, J. v., Vis, D., Lieftink, C., Linder, S., Beijersbergen, R., . . . Heijden, M. S. v. d. (2021). A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Nature Portfolio.
Style de citation Chicago (17e éd.)Palit, Sander A. L., Jeroen van Dorp, Daniel Vis, Cor Lieftink, Simon Linder, Roderick Beijersbergen, Andries M. Bergman, Wilbert Zwart, et Michiel S. van der Heijden. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.
Style de citation MLA (8e éd.)Palit, Sander A. L., et al. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.